when will retatrutide come out 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Retatrutide FDA Approval Status 2026:

We further replicated the SNP association in the All of Us cohort, using data derived from 4,855 people with EHR data

Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis

10.1016/S0014-5793(03)00727-0 FEBS Lett

In a systematic review of weight loss and imaging outcomes in overweight or obese individuals with hip or knee OA, Daugaard and colleagues concluded that there was no consistent evidence that weight loss altered structural OA pathology, while also emphasizing major heterogeneity in the structural endpoints used across studies (Daugaard et al., 2020)

This multi-system approach explains why GLP-1 before and after results look so different from traditional diet results

Applied Physiology, Nutrition, and Metabolism